HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tworetzky, W. Articles by Fineman, J. R. Search for Related Content PubMed PubMed Citation Articles by Tworetzky, W. Articles by Fineman, J. R.

CLINICAL STUDIES

Pulmonary blood flow alters nitric oxide production in patients undergoing device closure of atrial septal defects

^a Department of Pediatrics, University of California, San Francisco, San Francisco, California, USA

Manuscript received June 2, 1999; revised manuscript received September 21, 1999, accepted October 27, 1999.

Reprint requests and correspondence: Dr. Jeffrey R. Fineman, University of California, San Francisco, 505 Parnassus Avenue, Box 0106, M-680, San Francisco, California 94143-0106
jfineman{at}pedcard.ucsf.edu

OBJECTIVE

To determine the effect of pulmonary blood flow (Qp) on nitric oxide (NO) production in patients with increased Qp due to an atrial septal defect (ASD).

BACKGROUND

Alterations in pulmonary vascular NO production have been implicated in the development of pulmonary hypertension secondary to increased Qp. In vitro, acute changes in flow or shear stress alter NO production. However, the effect of Qp on lung NO production in vivo is unclear.

METHODS

Nineteen patients (2.4–61 years of age, median 17) with secundum ASD undergoing device closure were studied. Before, and 30 min after ASD closure, exhaled NO and plasma nitrate concentration were measured by chemiluminescence (NOA 280, Sievers, Boulder, Colorado).

RESULTS

Before ASD closure, all patients had increased Qp (Qp: systemic blood flow [Qs] of 2.0 ± 0.7) and normal mean pulmonary arterial pressure (13.4 ± 3.1 mm Hg). Atrial septal defect device closure decreased Qp from 6.0 ± 2.5 to 3.6 ± 1.3 L/min/m² (p < 0.05). Mean pulmonary arterial pressure was unchanged. Associated with the decrease in Qp, both exhaled NO (–22.1%, p < 0.05) and plasma nitrate concentrations (–17.9%, p < 0.05) decreased.

CONCLUSIONS

These data represent the first demonstration that acute changes in Qp alter pulmonary NO production in vivo in humans. Exhaled NO determinations may provide a noninvasive assessment of pulmonary vascular NO production in patients with congenital heart disease. Potential correlations between exhaled NO, pulmonary vascular reactivity and pulmonary hypertension warrant further study.

Abbreviations and Acronyms   ASD = atrial septal defect   cGMP = guanisone 3',5'-cyclic monophosphate   eNOS = endothelial NO synthase   NO = nitric oxide   NOx = nitrate   Qp = pulmonary blood flow   Qs = systemic blood flow   SD = standard deviation

This article has been cited by other articles:

				P. Oishi, A. Azakie, C. Harmon, R. K. Fitzgerald, A. Grobe, J. Xu, K. Hendricks-Munoz, S. M. Black, and J. R. Fineman Nitric oxide-endothelin-1 interactions after surgically induced acute increases in pulmonary blood flow in intact lambs Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1922 - H1932. [Abstract] [Full Text] [PDF]

				ATS Workshop Proceedings: Exhaled Nitric Oxide and Nitric Oxide Oxidative Metabolism in Exhaled Breath Condensate. Proceedings of the ATS, January 1, 2006; 3(2): 131 - 145. [Full Text] [PDF]

				C. Alexiou, A. T.M. Tang, D. C. Smith, S. V. Sheppard, M. P. Haw, and R. Gibbs Reply Ann. Thorac. Surg., November 1, 2005; 80(5): 1977 - 1978. [Full Text] [PDF]

				R. E. Girgis, H. C. Champion, G. B. Diette, R. A. Johns, S. Permutt, and J. T. Sylvester Decreased Exhaled Nitric Oxide in Pulmonary Arterial Hypertension: Response to Bosentan Therapy Am. J. Respir. Crit. Care Med., August 1, 2005; 172(3): 352 - 357. [Abstract] [Full Text] [PDF]

				ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005 Am. J. Respir. Crit. Care Med., April 15, 2005; 171(8): 912 - 930. [Full Text] [PDF]

				C. Alexiou, A. T.M. Tang, S. V. Sheppard, M. P. Haw, R. Gibbs, and D. C. Smith A Prospective Randomized Study to Evaluate the Effect of Leukodepletion on the Rate of Alveolar Production of Exhaled Nitric Oxide During Cardiopulmonary Bypass Ann. Thorac. Surg., December 1, 2004; 78(6): 2139 - 2145. [Abstract] [Full Text] [PDF]

				N. Marczin Exhaled nitric oxide and cardiac surgery with extracorporeal circulation J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1673 - 1674. [Full Text] [PDF]

				I. Adatia, T. Humpl, and P. E. Silkoff Reply to the editor J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1674 - 1675. [Full Text] [PDF]

				T. Humpl, R. Campbell, D. Stephens, G. Van Arsdell, L. N. Benson, H. M. Holtby, A. S. Slutsky, and I. Adatia Levels of exhaled nitric oxide before and after surgical and transcatheter device closure of atrial septal defects in children J. Thorac. Cardiovasc. Surg., October 1, 2002; 124(4): 806 - 810. [Abstract] [Full Text] [PDF]

				T. Ogasa, H. Nakano, H. Ide, Y. Yamamoto, N. Sasaki, S. Osanai, Y. Akiba, K. Kikuchi, and J. Iwamoto Flow-mediated release of nitric oxide in isolated, perfused rabbit lungs J Appl Physiol, July 1, 2001; 91(1): 363 - 370. [Abstract] [Full Text] [PDF]